.jpeg)
What is Brigatinib (Alunbrig)? Complete Guide to ALK-Positive Lung Cancer Targeted Therapy & Medication Guidelines
I. Understanding Brigatinib: Breakthrough of Second-Generation ALK Inhibitors
Brigatinib (Brand name: Alunbrig®) is a potent, highly selective oral second-generation tyrosine kinase inhibitor (TKI), developed by American Ariad Pharmaceuticals (later acquired by Japanese Takeda Pharmaceutical). The drug received accelerated approval in the United States in April 2017 and was officially approved by China's National Medical Products Administration in March 2022, entering clinical application in July of the same year through the first prescription at Shanghai Chest Hospital.
As a representative drug of second-generation ALK inhibitors, Brigatinib is specifically indicated for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene fusion mutations. These patients have abnormally fused ALK genes in their bodies, leading to continuous activation of ALK proteins that promote cancer cell proliferation, migration, and survival. Brigatinib achieves precision targeted therapy by highly selectively inhibiting ALK kinase activity and directly interfering with cancer cell signal transduction.
II. Core Advantages: Broad-Spectrum Anti-Mutation and Excellent Brain Penetration
Brigatinib has become one of the core drugs for ALK-positive lung cancer treatment, mainly due to the following two core advantages:
1. Broad-Spectrum Anti-ALK Resistance Mutations
Brigatinib has efficient inhibitory capacity against multiple resistance mutations generated after first-generation ALK inhibitor (such as Crizotinib) treatment, including common resistance sites like L1196M, G1202R, and L1152R. Its unique dimethylphosphine oxide (DMPO) molecular structure enhances binding affinity with ALK proteins, effectively covering multiple ALK fusion types and resistance mutations, providing new treatment options for previously treated patients.
Brigatinib has efficient inhibitory capacity against multiple resistance mutations generated after first-generation ALK inhibitor (such as Crizotinib) treatment, including common resistance sites like L1196M, G1202R, and L1152R. Its unique dimethylphosphine oxide (DMPO) molecular structure enhances binding affinity with ALK proteins, effectively covering multiple ALK fusion types and resistance mutations, providing new treatment options for previously treated patients.
2. Excellent Blood-Brain Barrier Penetration
Lung cancer brain metastasis is a major challenge faced by ALK-positive patients. Brigatinib has excellent brain penetration activity, effectively crossing the blood-brain barrier to achieve effective drug concentrations in brain tissue. Clinical data shows that Brigatinib's control rate for brain metastasis lesions is significantly superior to first-generation drugs, significantly reducing the risk of brain metastasis occurrence or effectively controlling existing brain metastasis lesions.
Lung cancer brain metastasis is a major challenge faced by ALK-positive patients. Brigatinib has excellent brain penetration activity, effectively crossing the blood-brain barrier to achieve effective drug concentrations in brain tissue. Clinical data shows that Brigatinib's control rate for brain metastasis lesions is significantly superior to first-generation drugs, significantly reducing the risk of brain metastasis occurrence or effectively controlling existing brain metastasis lesions.
III. Indications and Target Populations
According to indications approved by China's National Medical Products Administration, Brigatinib is suitable for the following populations:
1. First-Line Treatment
Adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer can use it as one of the preferred initial treatment options.
Adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer can use it as one of the preferred initial treatment options.
2. Second-Line and Later-Line Treatment
For patients who experienced disease progression or intolerance after previous Crizotinib treatment, Brigatinib can serve as an important option for subsequent treatment.
For patients who experienced disease progression or intolerance after previous Crizotinib treatment, Brigatinib can serve as an important option for subsequent treatment.
3. Special Population Considerations
ALK-positive patients with brain metastases should prioritize Brigatinib due to its excellent intracranial control capability. For patients with specific ALK resistance mutations, Brigatinib can be selected for targeted treatment after genetic testing confirmation.
ALK-positive patients with brain metastases should prioritize Brigatinib due to its excellent intracranial control capability. For patients with specific ALK resistance mutations, Brigatinib can be selected for targeted treatment after genetic testing confirmation.
IV. Dosage, Administration, and Medication Precautions
1. Standard Dosage
The recommended starting dose of Brigatinib is 90mg, once daily, orally, for 7 consecutive days. If the patient tolerates well, from day 8 the dose can be increased to 180mg, once daily. This stepwise dose escalation regimen helps reduce the incidence of early adverse reactions.
The recommended starting dose of Brigatinib is 90mg, once daily, orally, for 7 consecutive days. If the patient tolerates well, from day 8 the dose can be increased to 180mg, once daily. This stepwise dose escalation regimen helps reduce the incidence of early adverse reactions.
2. Administration Method
The drug can be taken with or without food. It is recommended to take it at a fixed time daily to maintain stable blood drug concentration. Tablets should be swallowed whole, not crushed, chewed, or split.
The drug can be taken with or without food. It is recommended to take it at a fixed time daily to maintain stable blood drug concentration. Tablets should be swallowed whole, not crushed, chewed, or split.
3. Missed Dose Management
If a dose is missed and there are more than 6 hours until the next scheduled dose, take it as soon as possible. If there are less than 6 hours until the next dose, skip the missed dose and take the next dose as scheduled. Never take double doses.
If a dose is missed and there are more than 6 hours until the next scheduled dose, take it as soon as possible. If there are less than 6 hours until the next dose, skip the missed dose and take the next dose as scheduled. Never take double doses.
4. Contraindications
Contraindicated in patients hypersensitive to Brigatinib or any excipient ingredients. Contraindicated in pregnant and breastfeeding women. Effective contraception measures should be taken during treatment and for at least 4 months after discontinuation.
Contraindicated in patients hypersensitive to Brigatinib or any excipient ingredients. Contraindicated in pregnant and breastfeeding women. Effective contraception measures should be taken during treatment and for at least 4 months after discontinuation.
V. Side Effect Management and Monitoring
Brigatinib's side effects are relatively manageable, but patients still need to closely monitor the following common adverse reactions:
1. Early Adverse Reactions (First 7 Days of Treatment)
Some patients may experience mild pneumonia-like symptoms during the initial treatment phase, including cough, dyspnea, and fever. This is a unique early pulmonary event associated with Brigatinib, and the 7-day stepwise dose escalation regimen can significantly reduce its incidence. If severe respiratory symptoms occur, seek medical attention immediately.
Some patients may experience mild pneumonia-like symptoms during the initial treatment phase, including cough, dyspnea, and fever. This is a unique early pulmonary event associated with Brigatinib, and the 7-day stepwise dose escalation regimen can significantly reduce its incidence. If severe respiratory symptoms occur, seek medical attention immediately.
2. Common Side Effects
Gastrointestinal reactions: nausea, diarrhea, vomiting, constipation, can be relieved through dietary adjustments or symptomatic medications.
Gastrointestinal reactions: nausea, diarrhea, vomiting, constipation, can be relieved through dietary adjustments or symptomatic medications.
Liver function abnormalities: regularly monitor liver function indicators; adjust dose or suspend medication if significant elevation occurs.
Hypertension: some patients may experience elevated blood pressure, requiring regular monitoring and antihypertensive medications as needed.
Musculoskeletal pain: joint pain, back pain, limb pain, can be relieved through rest or pain medications.
3. Rare but Serious Adverse Reactions
Interstitial lung disease: discontinue medication immediately and seek medical attention if persistent cough or worsening dyspnea occurs.
Interstitial lung disease: discontinue medication immediately and seek medical attention if persistent cough or worsening dyspnea occurs.
Bradycardia: regularly monitor heart rate; adjust dose if significant bradycardia occurs.
Visual disturbances: promptly inform your doctor if symptoms like blurred vision or light sensitivity occur.
4. Monitoring Recommendations
Before treatment: complete baseline examinations, including blood routine, liver and kidney function, electrocardiogram, lung CT, etc.
Before treatment: complete baseline examinations, including blood routine, liver and kidney function, electrocardiogram, lung CT, etc.
During treatment: re-examine every 2 weeks for the first 3 months, then monthly once stable. Focus on monitoring liver function, blood pressure, heart rate, and pulmonary symptoms.
VI. Latest Clinical Advances and Treatment Strategies
1. BRIGHTSTAR Study (2025 WCLC)
The BRIGHTSTAR study presented at the 2025 World Conference on Lung Cancer prospectively explored for the first time the efficacy of Brigatinib combined with local consolidative therapy (LCT) in ALK-positive advanced NSCLC patients. Results showed that this combination strategy significantly extends patient progression-free survival, providing new treatment directions for patients with deep responses.
The BRIGHTSTAR study presented at the 2025 World Conference on Lung Cancer prospectively explored for the first time the efficacy of Brigatinib combined with local consolidative therapy (LCT) in ALK-positive advanced NSCLC patients. Results showed that this combination strategy significantly extends patient progression-free survival, providing new treatment directions for patients with deep responses.
2. Brilliant Real-World Study
The Brilliant study reported by Chinese scholars at 2025 WCLC analyzed the characteristics and safety of Brigatinib as first-line treatment for Chinese ALK-positive NSCLC patients. Real-world data confirmed that Brigatinib has good efficacy and manageable safety in the Chinese population, consistent with global clinical trial results.
The Brilliant study reported by Chinese scholars at 2025 WCLC analyzed the characteristics and safety of Brigatinib as first-line treatment for Chinese ALK-positive NSCLC patients. Real-world data confirmed that Brigatinib has good efficacy and manageable safety in the Chinese population, consistent with global clinical trial results.
3. Combination Therapy Exploration
Current clinical research is exploring the combined application of Brigatinib with other targeted drugs, immunotherapy, or chemotherapy, aiming to further extend patient survival and overcome resistance issues.
Current clinical research is exploring the combined application of Brigatinib with other targeted drugs, immunotherapy, or chemotherapy, aiming to further extend patient survival and overcome resistance issues.
VII. Patient Life Management and Long-Term Follow-Up
1. Daily Life Recommendations
Maintain regular routines and avoid excessive fatigue. Diet should be light and easily digestible, with high intake of high-protein, high-vitamin foods. Quit smoking and limit alcohol, avoid exposure to secondhand smoke and harmful chemicals. Moderate exercise, such as walking, yoga, and other low-intensity activities, helps improve physical condition.
Maintain regular routines and avoid excessive fatigue. Diet should be light and easily digestible, with high intake of high-protein, high-vitamin foods. Quit smoking and limit alcohol, avoid exposure to secondhand smoke and harmful chemicals. Moderate exercise, such as walking, yoga, and other low-intensity activities, helps improve physical condition.
2. Drug Interactions
Brigatinib is metabolized by liver CYP3A4 enzymes. Avoid concurrent use with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampin, carbamazepine). If combination medication is needed, inform your doctor in advance about all medications currently being taken, including prescription drugs, over-the-counter drugs, and herbal medicines.
Brigatinib is metabolized by liver CYP3A4 enzymes. Avoid concurrent use with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampin, carbamazepine). If combination medication is needed, inform your doctor in advance about all medications currently being taken, including prescription drugs, over-the-counter drugs, and herbal medicines.
3. Long-Term Follow-Up Plan
Conduct a comprehensive evaluation every 3 months during treatment, including imaging examinations, tumor marker testing, and quality of life assessment. Even after achieving complete response, continue regular follow-up to timely detect disease progression or late adverse reactions.
Conduct a comprehensive evaluation every 3 months during treatment, including imaging examinations, tumor marker testing, and quality of life assessment. Even after achieving complete response, continue regular follow-up to timely detect disease progression or late adverse reactions.
4. Treatment Options After Resistance
If disease progression occurs, genetic testing should be repeated to clarify the resistance mechanism. Possible subsequent options include: third-generation ALK inhibitors (such as Lorlatinib), chemotherapy combined with anti-angiogenic drugs, local radiotherapy for oligoprogressive lesions, or participation in clinical trials.
If disease progression occurs, genetic testing should be repeated to clarify the resistance mechanism. Possible subsequent options include: third-generation ALK inhibitors (such as Lorlatinib), chemotherapy combined with anti-angiogenic drugs, local radiotherapy for oligoprogressive lesions, or participation in clinical trials.
VIII. Summary and Outlook
As an outstanding representative of second-generation ALK inhibitors, Brigatinib has become an important option for ALK-positive non-small cell lung cancer treatment, with its broad-spectrum anti-mutation capability, excellent intracranial control effects, and manageable safety profile.
In the future, with optimization of combination therapy strategies, deeper understanding of resistance mechanisms, and development of new-generation drugs, the survival and quality of life of ALK-positive lung cancer patients are expected to further improve. Patients should, under the guidance of professional oncologists, develop the most suitable treatment plan based on individual genetic profiling, disease staging, and physical condition, and adhere to standardized medication and regular follow-up to achieve optimal treatment outcomes.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
